From FDA: 7-26-19 FDA approves Boxed Warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib (Xeljanz, Xeljanz XR)

An excerpt:

The U.S. Food and Drug Administration has approved new warnings about an increased risk of blood clots and of death with the 10 mg twice daily dose of tofacitinib (Xeljanz, Xeljanz XR), which is used in patients with ulcerative colitis…

Health care professionals should discontinue tofacitinib and promptly evaluate patients with symptoms of thrombosis. Counsel patients about the risks and advise them to seek medical attention immediately if they experience any unusual symptoms, including those of thrombosis listed above. Reserve tofacitinib to treat ulcerative colitis for patients who have failed or do not tolerate tumor necrosis factor (TNF) blockers. Avoid tofacitinib in patients who may have a higher risk of thrombosis. When treating ulcerative colitis, use tofacitinib at the lowest effective dose and limit the use of the 10 mg twice daily dosage to the shortest duration needed

• 19 cases of blood clots in the lung out of 3,884 patient-years of follow-up in patients who received tofacitinib 10 mg twice daily, compared to 3 cases out of 3,982 patient-years in patients who received TNF blockers

Related blog posts:

• How Quickly Does Tofacitinib Work for Ulcerative Colitis?
• Tofacitinib -Where Does it Fit in Treatment Algorithm for Ulcerative Colitis?
• Tofacitinib Case Reports for Acute Severe UC and Pyoderma Gangrenosum
• Tofacitinib for Induction and Maintenance of Ulcerative Colitis
• AGA Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis
• Management of Acute Severe Colitis | gutsandgrowth
• Latest on Tofacitinib for Refractory Ulcerative Colitis
• Tofacitinib –a JAK Inhibitor for UC
• Tofacitinib -Risks and Benefits in Rheumatoid Arthritis

University of Virginia